

A knowledge-based T^2 -statistic to perform pathway analysis for quantitative proteomic data

June En-Yu Lai


TIGP Bioinformatics Program, Academia Sinica, Taiwan

August 18, 2017


Functional Analysis for Quantitative Proteomic Data

- Proteomic data v.s. gene expression data
 - ► Smaller sample size (number of experiments).
 - Fewer identified entities.
 - ► The results are sensitive to experimental conditions and instruments.
- ► Functional analysis
 - ► Pathway analysis (PLoS Computational Biology, 2017).
 - Responsive subpathway locating (working manuscript).

Pathway analysis — Data interpretation





Null hypothesis: Self-contained v.s. Competitive





Test statistic: Multivariate v.s. Univariate





The T^2 -statistic for pathway analysis

The proposed T^2 -statistic for a specific pathway $\mathcal P$ is then defined as,

$$T^2 = \mathbf{x}^T \mathbf{S}^{-1} \mathbf{x} \sim \chi_q^2$$

where

x is the vector of expression ratios,

 \mathbf{x}^T is the transpose of \mathbf{x} ,

 S^{-1} is the inverse of **the covariance matrix** S, and q is the number of mapped proteins in \mathcal{P} .

The T^2 -statistic for pathway analysis

- We use the confidence score provided by protein-protein interaction databases to represent the strength of the covariance, and the expression direction provided by the testing dataset to indicate the sign of the covariance.
- ▶ On the basis of the confidence scores in \mathfrak{I} and the protein expression ratios, each element s_{ij} of \mathfrak{S} is determined by the following four rules:

$$s_{ij} = \begin{cases} 0.4 & \text{if } i = j. \\ c_{p_i p_j} & \text{if } i \neq j, c_{p_i p_j} \in \mathfrak{I}, \text{ and } x_i \cdot x_j \geq 0. \\ -c_{p_i p_j} & \text{if } i \neq j, c_{p_i p_j} \in \mathfrak{I}, \text{ and } x_i \cdot x_j < 0. \\ 0.0 & \text{if } i \neq j \text{ and } c_{p_i p_j} \notin \mathfrak{I}. \end{cases}$$

The T^2 -statistic for pathway analysis

$$T^2 = \boldsymbol{x}^T \boldsymbol{S}^{-1} \boldsymbol{x} \sim \chi_q^2$$

- ▶ If *S* is degenerate, we construct a Moore-Penrose pseudoinverse of *S* as a substitute, and *q* becomes the rank of *S*.
- ▶ The *p*-value of the pathway $\mathcal P$ is derived from the χ^2_q distribution.

Pathway integration Pathway A n/a expressed n/a no evidence for pathway B


Performance evaluation — Really HARD!!!


- ► No accepted gold-standards.
- ▶ We tried to match the results reported by these methods to the biological ideas provided by the original publication (true positives).
- ► A good statistic should be able to test if a pathway is significant:
 - if a statistic reports very little significant pathways, it might have the problem of false negatives;
 - if a statistic reports a large number of significant pathways, it might have the problem of false positive.
- ▶ We supposed that the number of significant pathways is one of the attribute to evaluate these methods.

General comparison

| Tools | Significance requirement | Ranking statistic |
|-------|---|---------------------------|
| T^2 | raw <i>p</i> -value ≤ 0.05 | number of mapped proteins |
| DPA | raw <i>p</i> -value ≤ 0.05 | <i>p</i> -value |
| GSEA | FDR adjusted <i>p</i> -value (i.e. <i>q</i> -value) ≤ 0.25 | NES |
| DAVID | $EASE \le 0.1$ | <i>p</i> -value |
| IPA | Benjamini corrected p -value ≤ 0.05 | p-value |

General comparison: Consistency






General comparison: Consistency

| Database | | | KEGG | 1 | | | R | leactome | | | IPA |
|-------------|-----|-------|------|----------------|-------|-----|------|----------|------|-------|-----|
| Method | 2+5 | 2+XIR | DPA | CSEA | DAVID | 2+5 | 2+HR | DPA | CSEA | DAVID | IPA |
| Uniprot | + | + | 74 | - | + | + | + | + | - | - | - |
| IPA | + | + | /- | -// | + | + | + | + | _ | _ | _ |
| STRING | + | + | _ | / / | + | + | + | + | - | + | _ |
| HitPredict | + | + | | _ | + | + | + | + | _ | + | _ |
| ST: low | + | + | _ | _ | + | + | + | + | - | _ | _ |
| ST: medium | + | + | _ | _ | + | + | + | + | | _ | _ |
| ST: high | + | + | _ | _ | + | + | + | + | _ | + | _ |
| ST: highest | + | + | _ | _ | + | + | + | + | _ | + | _ |
| HP: low | + | + | _ | _ | + | + | + | + | _ | _ | _ |
| HP: high | + | + | - | _ | + | + | + | + | - | _ | _ |

General comparison: Target pathways

| Dataset | | TCR | | PI | ζA | Myog | enesis | CA | ИL | МАРК |
|------------------------------------|--------------------------------------|--------------------------|------------------|-------------------|-------------------|-----------------------------|-------------------|------------------------|--------------------|-------------------|
| Treatment | | α -CD3 ϵ | | PGE2 | | Serum-free | | Dasatinib | | U0126 |
| | 5 min | 15 min | 60 min | 1 min | 60 min | 24 hr | 72 hr | 5 nM | 50 nM | 10 μΜ |
| KEGG pathway | T cell receptor signaling pathway | | | | | Chronic myeloid leukemia | | MAPK signaling pathway | | |
| T ² ×ST p-value | 1/13 < 0.0001 | 1/57 < 0.0001 | 2/36 0.0019 | 16/45 < 0.0001 | 17/47 < 0.0001 | 15/54 < 0.0001 | 16/75 < 0.0001 | 20/111 < 0.0001 | 23/119 < 0.0001 | 3/118 < 0.0001 |
| $T^2 \times HP$ _{p-value} | 1/14 < 0.0001 | 1/59 0.0002 | 2/17 0.0011 | 17/49 < 0.0001 | 18/51 < 0.0001 | 16/56 < 0.0001 | 15/70 < 0.0001 | 20/113 < 0.0001 | 25/121 < 0.0001 | 3/117 < 0.0001 |
| DPA p-value | - | 8/68 0.0007 | 20/71 0.0024 | 11/15 0.0414 | 7/19 0.0178 | 18/73 0.0004 | | | <i>j</i> - | 2/17 0.0007 |
| GSEA q-value | 68/69 0.1786 | 7/60 0.1039 | - | - | - | 22/31 0.1416 | - | - | - | - |
| DAVID p-value | 1/47 < 0.0001 | 1/53 < 0.0001 | 1/35 < 0.0001 | - | - | 40/73 0.0041 | 40/73 0.0041 | 8/54 0.0004 | 8/54 0.0004 | 8/119 0.0002 |
| IPA p-value | 1/225 < 0.0001 | 2/232 < 0.0001 | 89/185 0.0022 | 60/79 0.0186 | 60/79 0.0191 | - | - | 52/129 0.0013 | 52/129 0.0013 | - |


Case Study: TCR downstream phosphoproteome



Case Study: TCR downstream phosphoproteome

| Dataset | Pathway Title | $\mathbf{T}^2 \times ST$ | $\mathbf{T}^2 \times HT$ | DPA | GSEA | DAVID | IPA |
|---------|---|--------------------------|--------------------------|-------|-------|-------|---------|
| 5 min | T cell rec <mark>eptor signaling pathway</mark> | 1/13 | 1/14 | 7-1 | 68/69 | 1/47 | 1/225 |
| | Ras signaling pathway | 2/57 | 2/59 | - \ | 1 - 1 | 10/53 | Main. |
| 15 . | Regulation of actin cytoskeleton | 3/57 | 3/59 | - | - | 9/53 | 15/232 |
| 15 min | MAPK signaling pathway | 4/57 | 4/59 | 65/68 | - | 41/53 | 4/232 |
| | PI3K-Akt signaling pathway | 24/57 | 25/59 | - | 6/60 | - | 169/232 |
| 60 min | mTOR signaling pathway | 25/36 | - | 67/71 | - | 24/35 | 68/185 |

Accurate and inaccurate estimation: Toy example



| | Correlated Data (generated by S) | Independent Data (generated byï¡đ <i>I</i>) |
|---|--|---|
| Correlated Null (normalized by S) | M2: accurate estimation | M4: inaccurate due to false positive PPI scores |
| Independent Null (normalized by <i>I</i>) | M3: inaccurate due to incomplete knowledge | M1: accurate estimation |

Accurate and inaccurate estimation: Real cases

| Dataset | Experiment | Pathway Title | original <i>p</i> -value | 30% permuted | 60% permuted | 30% purged | 60% purged |
|---------|------------|-----------------------------------|-----------------------------|-----------------|-----------------|---------------|---------------|
| - | 5 min | T cell receptor signaling pathway | < 0.0001 | 100% | 100% | 100% | 100% |
| | A | Ras signaling pathway | 0.0017 | 100% | 100% | 100% | 100% |
| TCR | 15 min | Regulation of actin cytoskeleton | < 0.0001 | 100% | 100% | 100% | 100% |
| ICK | is min | MAPK signaling pathway | < 0.0001 | 100% | 100% | 100% | 100% |
| | | PI3K-Akt signaling pathway | < 0.0001 | 100% | 100% | 100% | 100% |
| _ | 60 min | mTOR signaling pathway | 0.0002 | 97% | 98% | 100% | 100% |
| | 1 min | Regulation of actin cytoskeleton | < 0.0001 | 100% | 100% | 100% | 100% |
| | | PI3K-Akt signaling pathway | < 0.0001 | 92% | 81% | 86% | 84% |
| | | MAPK signaling pathway | < 0.0001 | 100% | 100% | 100% | 100% |
| | | Rap1 signaling pathway | < 0.0001 | 100% | 100% | 100% | 100% |
| PKA | | cAMP signaling pathway | < 0.0001 | 100% | 100% | 100% | 100% |
| - | | Glycolysis / Gluconeogenesis | 1 | 0% | 0% | 0% | 0% |
| | | Cell cycle | < 0.0001 | 100% | 100% | 100% | 100% |
| | 60 min | mTOR signaling pathway | 0.0024 | 100% | 100% | 100% | 100% |
| | | Base excision repair | < 0.0001 | 100% | 100% | 100% | 100% |

